EUVIMEDEUVIMED entdecken
Crossref

Peptide‐drug conjugate designated for targeted delivery to HER2‐expressing cancer cells

Amit Kumar Sharma, Rohit Sharma, Nitish Chauhan, Amit Das, Drishty Satpati iD

Journal of Peptide Science · 2024

DOI: 10.1002/psc.3602 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Peptide Science, 2024. Verfasst von Amit Kumar Sharma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Doxorubicin, Peptides, Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted therapy of the highest globally incident breast cancer shall resolve the issue of off‐target toxicity concurring with augmented killing of specific diseased cells. Thus, the goal of this study was to prepare a peptide‐drug conjugate targeting elevated expression of HER2 receptors in breast cancer. Towards this, the rL‐A9 peptide was conjugated with the chemotherapeutic drug doxorubicin (DOX) through a N ‐succinimidyl‐4‐( N ‐maleimidomethyl) cyclohexane‐1‐carboxylate (SMCC) linker. The synthesized peptide‐drug conjugate, rL‐A9‐DOX, was characterized by mass spectrometry. Molecular docking studies, based on binding energy data, suggested a stronger interaction of rL‐A9‐DOX with the HER2 receptor in comparison to the unconjugated peptide, rL‐A9. The cytotoxic effect of the rL‐A9‐DOX conjugate was observed to be higher in HER2‐positive SKOV3 cells compared to HER2‐negative MDA‐MB‐231 cells, indicating selective cell killing. Cellular internalization of the rL‐A9‐DOX conjugate was evident from the flow cytometry analysis, where a noticeable shift in mean fluorescent intensity (MFI) was observed for the conjugate compared to the control group. This data was further validated by confocal microscopy, where the fluorescent signal ascertained nuclear accumulation of rL‐A9‐DOX. The present studies highlight the promising potential of rL‐A9‐DOX for targeted delivery of the drug into a defined group of cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesDoxorubicinPeptidesBreast NeoplasmsHumansCell Line, TumorFemaleDrug Delivery SystemsMolecular Docking SimulationAntineoplastic AgentsDrug Screening Assays, AntitumorCell SurvivalDrug Carriers

Stichwörter der Autor:innen

HER2cytotoxicitydoxorubicinpeptide‐drug conjugaterL‐A9

Substanzen

Erb-b2 Receptor Tyrosine KinasesDoxorubicinPeptidesAntineoplastic AgentsDrug CarriersERBB2 protein, human

Autor:innen und Institutionen

  • Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.
  • Homi Bhabha National Institute, Mumbai, India.
  • Bio-Organic Division, Bhabha Atomic Research Centre, Mumbai, India.
  • Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Mumbai, India.

ORCID-Profile: Drishty Satpati

Zitieren

APA

Sharma, A. K., Sharma, R., Chauhan, N., Das, A., & Satpati, D. (2024). Peptide‐drug conjugate designated for targeted delivery to HER2‐expressing cancer cells. Journal of Peptide Science. https://doi.org/10.1002/psc.3602

Vancouver

Sharma AK, Sharma R, Chauhan N, Das A, Satpati D. Peptide‐drug conjugate designated for targeted delivery to HER2‐expressing cancer cells. Journal of Peptide Science. 2024. doi:10.1002/psc.3602

BibTeX
@article{Sharma2024,
  author = {Sharma, Amit Kumar and Sharma, Rohit and Chauhan, Nitish and Das, Amit and Satpati, Drishty},
  title = {Peptide‐drug conjugate designated for targeted delivery to HER2‐expressing cancer cells},
  journal = {Journal of Peptide Science},
  year = {2024},
  doi = {10.1002/psc.3602}
}
Kostenlos starten →